Clinical Trial Results:
A Phase 3 clinical study to determine the pharmacokinetics, safety, and efficacy of rVWF:rFVIII and rVWF in the treatment of bleeding episodes in subjects diagnosed with von Willebrand disease
Summary
|
|
EudraCT number |
2010-024108-84 |
Trial protocol |
GB DE SE AT NL BE BG IT ES |
Global end of trial date |
15 Feb 2014
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
12 Mar 2016
|
First version publication date |
07 Aug 2015
|
Other versions |
v1 |
Version creation reason |
|
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
071001
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01410227 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Baxalta Innovations GmbH
|
||
Sponsor organisation address |
Industriestrasse 67, Vienna, Austria, 1221
|
||
Public contact |
Clinical Trial Registries and Results Disclosure, Baxalta Innovations GmbH, ClinicalTrialsDisclosure@baxalta.com
|
||
Scientific contact |
Clinical Trial Registries and Results Disclosure, Baxalta Innovations GmbH, ClinicalTrialsDisclosure@baxalta.com
|
||
Sponsor organisation name |
Baxalta US Inc.
|
||
Sponsor organisation address |
One Baxter Way, Westlake Village, United States, CA 91362
|
||
Public contact |
Clinical Trial Registries and Results Disclosure, Baxalta US Inc., ClinicalTrialsDisclosure@baxalta.com
|
||
Scientific contact |
Clinical Trial Registries and Results Disclosure, Baxalta US Inc., ClinicalTrialsDisclosure@baxalta.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
15 Feb 2014
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
15 Feb 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The objectives of this study were:
To compare the pharmacokinetic (PK) parameters of recombinant von Willebrand Factor (rVWF) alone or concomitantly with recombinant Factor VIII (rFVIII) [rVWF:rFVIII] in subjects with type 3 von Willebrand Disease (VWD);
To examine the PK parameters of rVWF in subjects with severe VWD;
To evaluate the hemostatic efficacy, safety, and tolerability of rVWF:rFVIII and rVWF alone in subjects with VWD receiving the investigational product for the treatment of bleeding episodes (BEs);
To evaluate tolerability and safety of rVWF including the development of inhibitory and total binding anti-VWF antibodies and clinically significant changes in laboratory parameters following study product administration;
To assess changes in Health-Related Quality of Life (HRQoL)
|
||
Protection of trial subjects |
This study was conducted in accordance with the standards of Good Clinical Practice (GCP) in effect at the time of the study.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
17 Jan 2011
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Austria: 1
|
||
Country: Number of subjects enrolled |
Belgium: 1
|
||
Country: Number of subjects enrolled |
Bulgaria: 2
|
||
Country: Number of subjects enrolled |
Germany: 2
|
||
Country: Number of subjects enrolled |
Spain: 1
|
||
Country: Number of subjects enrolled |
United Kingdom: 3
|
||
Country: Number of subjects enrolled |
India: 1
|
||
Country: Number of subjects enrolled |
Italy: 3
|
||
Country: Number of subjects enrolled |
Japan: 3
|
||
Country: Number of subjects enrolled |
Netherlands: 1
|
||
Country: Number of subjects enrolled |
Poland: 6
|
||
Country: Number of subjects enrolled |
Australia: 2
|
||
Country: Number of subjects enrolled |
Russian Federation: 2
|
||
Country: Number of subjects enrolled |
Sweden: 1
|
||
Country: Number of subjects enrolled |
United States: 8
|
||
Worldwide total number of subjects |
37
|
||
EEA total number of subjects |
21
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
37
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recruitment details |
Subjects were enrolled (signed informed consent) from 30 sites in 15 countries. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Screening details |
49 subjects provided informed consent and were screened for study, of which 37 were exposed to study product. Reasons for discontinuation are provided in Pre-assignment period. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pre-assignment period milestones
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of subjects started |
49 [1] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of subjects completed |
37 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pre-assignment subject non-completion reasons
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reason: Number of subjects |
Consent withdrawn by subject: 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reason: Number of subjects |
Physician decision: 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reason: Number of subjects |
Screen failure: 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reason: Number of subjects |
High doses of rFVIII for oral procedure: 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reason: Number of subjects |
Arm for which subject eligible was closed: 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: The worldwide number of subjects enrolled are for subjects treated with study product (N=37) as per definition in EudraCT (Enrolled=Treated) and the number of subjects who started pre-assignment are all subjects enrolled i.e. signed informed consent (N=49). |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Period 1 title |
Overall Trial (Part A and B Combined) (overall period)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Roles blinded |
Investigator, Subject | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Blinding implementation details |
Part Randomized: Subjects in Arms 1 and 2 were randomized at ratio of 1:1 to receive either recombinant von Willebrand Factor:recombinant Factor VIII (rVWF:rFVIII) or rVWF:saline (placebo) for pharmacokinetic (PK) analysis. After a washout period, subjects crossed over to receive the alternative treatment to the initial infusion for a further PK analysis.
Subject/investigator were blinded and the study product was reconstituted by an unblinded third party (preferably by the hospital pharmacist)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
No
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
PK50+Treatment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
In Part A, (pharmacokinetic [PK] assessment followed by on-demand treatment for bleeding episodes [BEs] for 6 months) subjects were initially infused either with 50 IU/kg recombinant von Willebrand Factor:von Willebrand Ristocetin cofactor (VWF:RCo rVWF) [rVWF] administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) [rVWF:rFVIII] or 50 IU/kg rVWF administered together with saline. Subjects then crossed over to the alternate infusion after washout (PK). For on-demand treatment, subjects received study product [VWF:rFVIII or rVWF], where BEs were initially treated with rVWF:rFVIII and subsequently with rVWF with or without rFVIII, based on FVIII levels (dose based on previous FVIII levels or if not available from the individual subject's PK data at discretion of investigator). In part, B subjects continued to receive on demand treatment for BEs with study product [VWF:rFVIII or rVWF] for a further 6 months. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
rVWF:rFVIII
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
BAX111 with ADVATE
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
vonicog alfa with ADVATE
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
50 IU/kg von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] co-infused with 38.5 IU/kg recombinant Factor VIII (rFVIII) at a ratio of 1.3:1±0.2 [rVWF:rFVIII] (Arms 1 and 2 -PK50 only). Dose and frequency of study product for on-demand treatment of bleeding episodes for Arms 1, 3 and 4 dependent on severity and location of bleed. The initial bleeding episode was to be treated with rVWF:rFVIII at a ratio of 1.3:1±0.2 with subsequent doses of rVWF alone as long as therapeutic FVIII levels were maintained.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
rVWF
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
BAX111
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
vonicog alfa
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
50 IU/kg von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] (Arms 1 and 2 -PK50 only), 80 IU/kg VWF:RCo rVWF [rVWF] rVWF (Arm 3 - PK80 only). Dose and frequency of study product for on-demand treatment of bleeding episodes for Arms 1, 3 and 4 dependent on severity and location of bleed. The initial bleeding episode was to be treated with rVWF:rFVIII at a ratio of 1.3:1±0.2 with subsequent doses of rVWF alone as long as therapeutic FVIII levels were maintained
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
PK50 only | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
In Part A, (pharmacokinetic [PK] assessment followed by on-demand treatment for bleeding episodes [BEs] for 6 months) subjects were initially infused either with 50 IU/kg recombinant von Willebrand Factor:von Willebrand Ristocetin cofactor (VWF:RCo rVWF) [rVWF] administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) [rVWF:rFVIII] or 50 IU/kg rVWF administered together with saline. Subjects then crossed over to the alternate infusion after washout (PK). For on-demand treatment, subjects received study product [VWF:rFVIII or rVWF], where BEs were initially treated with rVWF:rFVIII and subsequently with rVWF with or without rFVIII, based on FVIII levels (dose based on previous FVIII levels or if not available from the individual subject's PK data at discretion of investigator). Subjects then exited the study or could opt to sign informed consent to move to Arm 1 receive treatment for bleeding episodes with study product. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
rVWF
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
BAX111
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
vonicog alfa
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
50 IU/kg von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] (Arms 1 and 2 -PK50 only), 80 IU/kg VWF:RCo rVWF [rVWF] rVWF (Arm 3 - PK80 only). Dose and frequency of study product for on-demand treatment of bleeding episodes for Arms 1, 3 and 4 dependent on severity and location of bleed. The initial bleeding episode was to be treated with rVWF:rFVIII at a ratio of 1.3:1±0.2 with subsequent doses of rVWF alone as long as therapeutic FVIII levels were maintained
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
rVWF:rFVIII
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
BAX111 with ADVATE
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
vonicog alfa with ADVATE
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
50 IU/kg von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] co-infused with 38.5 IU/kg recombinant Factor VIII (rFVIII) at a ratio of 1.3:1±0.2 [rVWF:rFVIII] (Arms 1 and 2 -PK50 only). Dose and frequency of study product for on-demand treatment of bleeding episodes for Arms 1, 3 and 4 dependent on severity and location of bleed. The initial bleeding episode was to be treated with rVWF:rFVIII at a ratio of 1.3:1±0.2 with subsequent doses of rVWF alone as long as therapeutic FVIII levels were maintained.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
PK80+Treatment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
In Part A, subjects underwent pharmacokinetic (PK) assessment for 2 infusions of recombinant von Willebrand Factor (rVWF). Subjects initially underwent an initial PK assessment of an infusion of 80 IU/kg recombinant von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF]. After the first PK assessment subjects received on demand treatment for bleeding episodes (BEs) with study product [VWF:rFVIII or rVWF], where BEs were initially treated with rVWF:rFVIII and subsequently with rWVF with or without rFVIII, based on FVIII levels. If FVIII levels not available, the individual subject's PK data was used to determine rFVIII dose at discretion of investigator. Subjects received on demand treatment for 6 months after the first study product infusion. After 6 months subjects underwent a second PK assessment of an infusion of 80 IU/kg rVWF. In part B, subjects continued to receive on demand treatment for BEs with study product [VWF:rFVIII or rVWF] for a further 6 months. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
rVWF
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
BAX111
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
vonicog alfa
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
50 IU/kg von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] (Arms 1 and 2 -PK50 only), 80 IU/kg VWF:RCo rVWF [rVWF] rVWF (Arm 3 - PK80 only). Dose and frequency of study product for on-demand treatment of bleeding episodes for Arms 1, 3 and 4 dependent on severity and location of bleed. The initial bleeding episode was to be treated with rVWF:rFVIII at a ratio of 1.3:1±0.2 with subsequent doses of rVWF alone as long as therapeutic FVIII levels were maintained
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
rVWF:rFVIII
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
BAX111 with ADVATE
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
vonicog alfa with ADVATE
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
50 IU/kg von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] co-infused with 38.5 IU/kg recombinant Factor VIII (rFVIII) at a ratio of 1.3:1±0.2 [rVWF:rFVIII] (Arms 1 and 2 -PK50 only). Dose and frequency of study product for on-demand treatment of bleeding episodes for Arms 1, 3 and 4 dependent on severity and location of bleed. The initial bleeding episode was to be treated with rVWF:rFVIII at a ratio of 1.3:1±0.2 with subsequent doses of rVWF alone as long as therapeutic FVIII levels were maintained.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Treatment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
In Part A, subjects received on demand treatment for bleeding episodes (BEs) with study product (recombinant von Willebrand Factor [rVWF] administered together with recombinant Factor VIII [rFVIII] (rVWF:rFVIII) or rVWF alone), where BEs were initially treated with rVWF:rFVIII and subsequently with rVWF with or without rFVIII, based on FVIII levels. If not available, the individual subject's PK data was used to determine rFVIII dose at discretion of investigator. Subjects received on demand treatment for 6 months after the first study product infusion. In part, B subjects continued to receive on demand treatment for BEs with study product [VWF:rFVIII or rVWF] for a further 6 months. No pharmacokinetic (PK) assessments were conducted in this arm. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
rVWF:rFVIII
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
BAX111 with ADVATE
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
vonicog alfa with ADVATE
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
50 IU/kg von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] co-infused with 38.5 IU/kg recombinant Factor VIII (rFVIII) at a ratio of 1.3:1±0.2 [rVWF:rFVIII] (Arms 1 and 2 -PK50 only). Dose and frequency of study product for on-demand treatment of bleeding episodes for Arms 1, 3 and 4 dependent on severity and location of bleed. The initial bleeding episode was to be treated with rVWF:rFVIII at a ratio of 1.3:1±0.2 with subsequent doses of rVWF alone as long as therapeutic FVIII levels were maintained.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
rVWF
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
BAX111
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
vonicog alfa
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
50 IU/kg von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] (Arms 1 and 2 -PK50 only), 80 IU/kg VWF:RCo rVWF [rVWF] rVWF (Arm 3 - PK80 only). Dose and frequency of study product for on-demand treatment of bleeding episodes for Arms 1, 3 and 4 dependent on severity and location of bleed. The initial bleeding episode was to be treated with rVWF:rFVIII at a ratio of 1.3:1±0.2 with subsequent doses of rVWF alone as long as therapeutic FVIII levels were maintained
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Safety Analysis Set | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
The Safety Analysis Set comprises of subjects who were treated with study product (recombinant von Willebrand Factor [rVWF] with or without recombinant factor VIII [rFVIII]) at least once during the study. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
rVWF
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
BAX111
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
vonicog alfa
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
50 IU/kg von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] (Arms 1 and 2 -PK50 only), 80 IU/kg VWF:RCo rVWF [rVWF] rVWF (Arm 3 - PK80 only). Dose and frequency of study product for on-demand treatment of bleeding episodes for Arms 1, 3 and 4 dependent on severity and location of bleed. The initial bleeding episode was to be treated with rVWF:rFVIII at a ratio of 1.3:1±0.2 with subsequent doses of rVWF alone as long as therapeutic FVIII levels were maintained
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
rVWF:rFVIII
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
BAX111 with ADVATE
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
vonicog alfa with ADVATE
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
50 IU/kg von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] co-infused with 38.5 IU/kg recombinant Factor VIII (rFVIII) at a ratio of 1.3:1±0.2 [rVWF:rFVIII] (Arms 1 and 2 -PK50 only). Dose and frequency of study product for on-demand treatment of bleeding episodes for Arms 1, 3 and 4 dependent on severity and location of bleed. The initial bleeding episode was to be treated with rVWF:rFVIII at a ratio of 1.3:1±0.2 with subsequent doses of rVWF alone as long as therapeutic FVIII levels were maintained.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Full Analysis Set | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
The Full Analysis Set comprised of subjects treated with study product (recombinant von Willebrand Factor [rVWF] with or without recombinant factor VIII [rFVIII]) for whom at least one efficacy rating scale was available. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
rVWF:rFVIII
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
BAX111 with ADVATE
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
vonicog alfa with ADVATE
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
50 IU/kg von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] co-infused with 38.5 IU/kg recombinant Factor VIII (rFVIII) at a ratio of 1.3:1±0.2 [rVWF:rFVIII] (Arms 1 and 2 -PK50 only). Dose and frequency of study product for on-demand treatment of bleeding episodes for Arms 1, 3 and 4 dependent on severity and location of bleed. The initial bleeding episode was to be treated with rVWF:rFVIII at a ratio of 1.3:1±0.2 with subsequent doses of rVWF alone as long as therapeutic FVIII levels were maintained.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
rVWF
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
BAX111
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
vonicog alfa
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
50 IU/kg von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] (Arms 1 and 2 -PK50 only), 80 IU/kg VWF:RCo rVWF [rVWF] rVWF (Arm 3 - PK80 only). Dose and frequency of study product for on-demand treatment of bleeding episodes for Arms 1, 3 and 4 dependent on severity and location of bleed. The initial bleeding episode was to be treated with rVWF:rFVIII at a ratio of 1.3:1±0.2 with subsequent doses of rVWF alone as long as therapeutic FVIII levels were maintained
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
PK50 Arms | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
The PK50 arm comprised of subjects who underwent PK analysis of study product (50 IU/kg recombinant von Willebrand Factor (rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) [rVWF:rFVIII] or 50 IU/kg rVWF administered together with saline [rVWF]) i.e. a total subjects from Arm 1 [PK50+Treatment] and Arm 2 [PK50 only]. Subjects in this arm have received at least one PK infusion and have provided data suitable for PK analysis. Only PK data included in this arm. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
rVWF:rFVIII
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
BAX111 with ADVATE
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
vonicog alfa with ADVATE
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
50 IU/kg von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] co-infused with 38.5 IU/kg recombinant Factor VIII (rFVIII) at a ratio of 1.3:1±0.2 [rVWF:rFVIII] (Arms 1 and 2 -PK50 only). Dose and frequency of study product for on-demand treatment of bleeding episodes for Arms 1, 3 and 4 dependent on severity and location of bleed. The initial bleeding episode was to be treated with rVWF:rFVIII at a ratio of 1.3:1±0.2 with subsequent doses of rVWF alone as long as therapeutic FVIII levels were maintained.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
rVWF
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
BAX111
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
vonicog alfa
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
50 IU/kg von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] (Arms 1 and 2 -PK50 only), 80 IU/kg VWF:RCo rVWF [rVWF] rVWF (Arm 3 - PK80 only). Dose and frequency of study product for on-demand treatment of bleeding episodes for Arms 1, 3 and 4 dependent on severity and location of bleed. The initial bleeding episode was to be treated with rVWF:rFVIII at a ratio of 1.3:1±0.2 with subsequent doses of rVWF alone as long as therapeutic FVIII levels were maintained
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
PK80 Arm | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
The PK80 arm comprised of subjects who underwent PK analysis of study product (80 IU/kg recombinant von Willebrand Factor [rVWF]) i.e. subjects from Arm 3 [PK80+Treatment]. Subjects in this arm have received at least one PK infusion and have provided data suitable for PK analysis. Only PK data included in this arm. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
rVWF
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
BAX111
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
vonicog alfa
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
50 IU/kg von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] (Arms 1 and 2 -PK50 only), 80 IU/kg VWF:RCo rVWF [rVWF] rVWF (Arm 3 - PK80 only). Dose and frequency of study product for on-demand treatment of bleeding episodes for Arms 1, 3 and 4 dependent on severity and location of bleed. The initial bleeding episode was to be treated with rVWF:rFVIII at a ratio of 1.3:1±0.2 with subsequent doses of rVWF alone as long as therapeutic FVIII levels were maintained
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||
Reporting group title |
Overall Trial (Part A and B Combined)
|
|||||||||||||||||||||||||||||||||
Reporting group description |
Overall Trial (Part A and B Combined) | |||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
PK50+Treatment
|
||
Reporting group description |
In Part A, (pharmacokinetic [PK] assessment followed by on-demand treatment for bleeding episodes [BEs] for 6 months) subjects were initially infused either with 50 IU/kg recombinant von Willebrand Factor:von Willebrand Ristocetin cofactor (VWF:RCo rVWF) [rVWF] administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) [rVWF:rFVIII] or 50 IU/kg rVWF administered together with saline. Subjects then crossed over to the alternate infusion after washout (PK). For on-demand treatment, subjects received study product [VWF:rFVIII or rVWF], where BEs were initially treated with rVWF:rFVIII and subsequently with rVWF with or without rFVIII, based on FVIII levels (dose based on previous FVIII levels or if not available from the individual subject's PK data at discretion of investigator). In part, B subjects continued to receive on demand treatment for BEs with study product [VWF:rFVIII or rVWF] for a further 6 months. | ||
Reporting group title |
PK50 only
|
||
Reporting group description |
In Part A, (pharmacokinetic [PK] assessment followed by on-demand treatment for bleeding episodes [BEs] for 6 months) subjects were initially infused either with 50 IU/kg recombinant von Willebrand Factor:von Willebrand Ristocetin cofactor (VWF:RCo rVWF) [rVWF] administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) [rVWF:rFVIII] or 50 IU/kg rVWF administered together with saline. Subjects then crossed over to the alternate infusion after washout (PK). For on-demand treatment, subjects received study product [VWF:rFVIII or rVWF], where BEs were initially treated with rVWF:rFVIII and subsequently with rVWF with or without rFVIII, based on FVIII levels (dose based on previous FVIII levels or if not available from the individual subject's PK data at discretion of investigator). Subjects then exited the study or could opt to sign informed consent to move to Arm 1 receive treatment for bleeding episodes with study product. | ||
Reporting group title |
PK80+Treatment
|
||
Reporting group description |
In Part A, subjects underwent pharmacokinetic (PK) assessment for 2 infusions of recombinant von Willebrand Factor (rVWF). Subjects initially underwent an initial PK assessment of an infusion of 80 IU/kg recombinant von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF]. After the first PK assessment subjects received on demand treatment for bleeding episodes (BEs) with study product [VWF:rFVIII or rVWF], where BEs were initially treated with rVWF:rFVIII and subsequently with rWVF with or without rFVIII, based on FVIII levels. If FVIII levels not available, the individual subject's PK data was used to determine rFVIII dose at discretion of investigator. Subjects received on demand treatment for 6 months after the first study product infusion. After 6 months subjects underwent a second PK assessment of an infusion of 80 IU/kg rVWF. In part B, subjects continued to receive on demand treatment for BEs with study product [VWF:rFVIII or rVWF] for a further 6 months. | ||
Reporting group title |
Treatment
|
||
Reporting group description |
In Part A, subjects received on demand treatment for bleeding episodes (BEs) with study product (recombinant von Willebrand Factor [rVWF] administered together with recombinant Factor VIII [rFVIII] (rVWF:rFVIII) or rVWF alone), where BEs were initially treated with rVWF:rFVIII and subsequently with rVWF with or without rFVIII, based on FVIII levels. If not available, the individual subject's PK data was used to determine rFVIII dose at discretion of investigator. Subjects received on demand treatment for 6 months after the first study product infusion. In part, B subjects continued to receive on demand treatment for BEs with study product [VWF:rFVIII or rVWF] for a further 6 months. No pharmacokinetic (PK) assessments were conducted in this arm. | ||
Reporting group title |
Safety Analysis Set
|
||
Reporting group description |
The Safety Analysis Set comprises of subjects who were treated with study product (recombinant von Willebrand Factor [rVWF] with or without recombinant factor VIII [rFVIII]) at least once during the study. | ||
Reporting group title |
Full Analysis Set
|
||
Reporting group description |
The Full Analysis Set comprised of subjects treated with study product (recombinant von Willebrand Factor [rVWF] with or without recombinant factor VIII [rFVIII]) for whom at least one efficacy rating scale was available. | ||
Reporting group title |
PK50 Arms
|
||
Reporting group description |
The PK50 arm comprised of subjects who underwent PK analysis of study product (50 IU/kg recombinant von Willebrand Factor (rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) [rVWF:rFVIII] or 50 IU/kg rVWF administered together with saline [rVWF]) i.e. a total subjects from Arm 1 [PK50+Treatment] and Arm 2 [PK50 only]. Subjects in this arm have received at least one PK infusion and have provided data suitable for PK analysis. Only PK data included in this arm. | ||
Reporting group title |
PK80 Arm
|
||
Reporting group description |
The PK80 arm comprised of subjects who underwent PK analysis of study product (80 IU/kg recombinant von Willebrand Factor [rVWF]) i.e. subjects from Arm 3 [PK80+Treatment]. Subjects in this arm have received at least one PK infusion and have provided data suitable for PK analysis. Only PK data included in this arm. |
|
|||||||||
End point title |
Percentage of subjects with treatment success for treated bleeding episodes [1] [2] | ||||||||
End point description |
Treatment success was defined as the extent of control of bleeding episodes (BEs) using a mean efficacy rating score of <2.5 for a subject’s BEs treated with study product (recombinant von Willebrand Factor [rVWF] with or without recombinant factor VIII [rFVIII]) during the study period.
Scores used:
Excellent = 1 - actual infusions ≤ estimated number of infusions required to treat BE; no additional VWF required (all BEs);
Good = 2 - >1-2 infusions (minor/moderate BEs) or <1.5 infusions (major BEs) greater than estimated required to control BE; no additional VWF required (all BEs);
Moderate = 3 ≥ 3 infusions (minor/moderate BEs) or ≥ 1.5 infusions (major BEs) greater than estimated required to control BE; no additional VWF required (all BEs);
None = 4 - severe uncontrolled bleeding or intensity of bleeding not changed; additional VWF required.
Included subjects with available primary efficacy rating (prospective-excluding gastrointestinal bleeds) in the Full Analysis Set
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
for 12 months after first infusion of rVWF:rFVIII or rVWF
|
||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Currently unable to enter statistics for one analysis group (Full Analysis Set). The null hypothesis H0: p ≤ 0.65 was tested against alternative hypothesis HA: p > 0.65 by two-sided Clopper Pearson 90% CI. Results: Success rate: 100% (90% CI: 84.7-100%). [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Refer to [1] |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Percentage of treated bleeding episodes treated with an efficacy rating of "excellent" or "good" [3] | ||||||||
End point description |
Efficacy ratings "excellent" or "good" for the control of bleeding episodes (BEs) with study product (recombinant von Willebrand Factor [rVWF] with or without recombinant factor VIII [rFVIII]) are defined as follows:
Excellent - actual infusions ≤ estimated number of infusions required to treat BE; no additional von Willebrand Factor (VWF) required (all BEs);
Good - >1-2 infusions (minor/moderate BEs) or <1.5 infusions (major BEs) greater than estimated required to control BE; no additional VWF required (all BEs).
The data set included prospectively estimated BEs [N=130] treated with study product with an available efficacy rating from subjects in the Full Analysis Set.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
for 12 months after first infusion of rVWF:rFVIII or rVWF
|
||||||||
Notes [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Currently unable to enter statistics for one analysis group (Full Analysis Set). The null hypothesis H0: p ≤ 0.65 was tested against alternative hypothesis HA: p > 0.65 by two-sided Clopper Pearson 90% CI. Results: Success rate: 100% (90% CI: 97.7-100%). |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Percentage of treated bleeding episodes with an efficacy rating of "excellent" or "good", excluding gastrointestinal bleeds [4] | ||||||||
End point description |
Efficacy ratings of "excellent" or "good" for the control of bleeding episodes (BEs) with study product (recombinant von Willebrand Factor [rVWF] with or without recombinant factor VIII [rFVIII]) are defined as follows:
Excellent - actual infusions ≤ estimated number of infusions required to treat BE; no additional von Willebrand Factor (VWF) required (all BEs);
Good - >1-2 infusions (minor/moderate BEs) or <1.5 infusions (major BEs) greater than estimated required to control BE; no additional VWF required (all BEs).
The data set included prospectively estimated BEs [N=126] excluding gastrointestinal (GI) bleeds treated with study product with an available efficacy rating from subjects in the Full Analysis Set.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
for 12 months after first infusion of rVWF:rFVIII or rVWF
|
||||||||
Notes [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Currently unable to enter statistics for one analysis group (Full Analysis Set). The null hypothesis H0: p ≤ 0.65 was tested against alternative hypothesis HA: p > 0.65 by two-sided Clopper Pearson 90% CI. Results: Success rate: 100% (90% CI: 84.7-100%). |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Number of infusions of rVWF:rFVIII and/or rVWF per bleeding episode [5] | ||||||||
End point description |
The actual number of infusions of recombinant von Willebrand factor:recombinant factor VIII (rVWF:rFVIII) and/or rVWF required to treat a bleeding episode (BE).
BEs were to be initially treated with an infusion of rVWF:rFVIII and subsequently with rVWF with or without rFVIII, based on FVIII levels, if available. In cases, where no FVIII levels were available, the individual subject’s PK data was used to determine the rFVIII dose.
The data set included prospectively estimated BEs [N=192] treated with study product with an available efficacy rating from subjects in the Full Analysis Set.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
for 12 months after first infusion of rVWF:rFVIII or rVWF
|
||||||||
Notes [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Number of units of rVWF:rFVIII and/or rVWF per bleeding episode [6] | ||||||||
End point description |
The number of units is provided as the actual dose [IU/kg] of recombinant von Willebrand factor:recombinant factor VIII (rVWF:rFVIII) and/or rVWF required to treat a bleeding episode (BE).
BEs were to be initially treated with an infusion of rVWF:rFVIII and subsequently with rVWF with or without rFVIII, based on FVIII levels, if available. In cases, where no FVIII levels were available, the individual subject’s PK data was used to determine the rFVIII dose. The data set included BEs [N=174] treated with study product of known lot number with an available efficacy rating from subjects in the Full Analysis Set.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
for 12 months after first infusion of rVWF:rFVIII or rVWF
|
||||||||
Notes [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of subjects who develop inhibitory antibodies to FVIII [7] | ||||||||||||||
End point description |
Development of neutralizing antibodies (inhibitors) to factor VIII (FVIII) was assessed by the Nijmegen modification of the Bethesda assay. Positive FVIII inhibitor tests were defined as ≥ 0.4 Bethesda units/mL (BU/mL) by the Nijmegen-modified Bethesda assay that is confirmed by a second test performed on an independent sample obtained 2-4 weeks following the first test.
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
After signing informed consent until 12 months after first infusion of rVWF:rFVIII or rVWF
|
||||||||||||||
Notes [7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of subjects who develop inhibitory antibodies to VWF [8] | ||||||||||||||
End point description |
Neutralizing antibodies (inhibitors) to Von Willebrand Factor Ristocetin cofactor (VWF:RCo), VWF collagen binding (VWF:CB) and VWF Factor VIII binding (VWF:FVIIIB) activities were measured using Nijmegen modification of the Bethesda assay. One Bethesda Unit (BU) is thereby defined as the amount of inhibitor that decreased the measured activity in the assays to 50% of that of the negative control samples. The assays were validated using human plasma samples from two type 3 VWD patients with low (1-2 BU/mL) and high (~10 BU/mL) titer inhibitors and plasma samples from non-human primates immunized with human rVWF (>100 BU/mL).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
After signing informed consent until 12 months after first infusion of rVWF:rFVIII or rVWF
|
||||||||||||||
Notes [8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Arms in the baseline period are not mutually exclusive - refer to Arm Descriptions in Period 1 (baseline period). Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of subjects who develop binding antibodies to VWF [9] | ||||||||||||||
End point description |
The presence of total binding anti-VWF antibodies was determined by an enzyme-linked immunosorbent assay (ELISA) employing polyclonal anti-human immunoglobulin (Ig) antibodies (IgG, IgM and IgA).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
After signing informed consent until 12 months after first infusion of rVWF:rFVIII or rVWF
|
||||||||||||||
Notes [9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of subjects who develop binding antibodies to CHO [10] | ||||||||||||||
End point description |
The presence of total binding anti-CHO antibodies was determined by measuring total immunoglobulin (Ig) antibodies (IgG, IgA, IgM) against Chinese Hamster Ovary (CHO) protein using an enzyme-linked immunosorbent assay (ELISA).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
After signing informed consent until 12 months after first infusion of rVWF:rFVIII or rVWF
|
||||||||||||||
Notes [10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of subjects who develop binding antibodies to rFurin [11] | ||||||||||||||
End point description |
The presence of total binding anti-rFurin antibodies was determined by measuring total immunoglobulin (Ig) antibodies (IgG, IgA, IgM) against rFurin protein using an enzyme-linked immunosorbent assay (ELISA).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
After signing informed consent until 12 months after first infusion of rVWF:rFVIII or rVWF
|
||||||||||||||
Notes [11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of subjects who develop binding antibodies to mouse immunoglobulin [12] | ||||||||||||||
End point description |
The presence of total binding anti-Murine immunoglobulin (IgG) antibodies was determined using an enzyme-linked immunosorbent assay (ELISA).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
After signing informed consent until 12 months after first infusion of rVWF:rFVIII or rVWF
|
||||||||||||||
Notes [12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Percentage of subjects who had an occurrence of thrombotic events [13] | ||||||||
End point description |
|||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
After signing informed consent until 12 months after first infusion of rVWF:rFVIII or rVWF
|
||||||||
Notes [13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Number of adverse events related to study product including clinically significant changes in laboratory parameters and vital signs [14] | ||||||||||||||||||||||
End point description |
Adverse Events (AEs) related to study product (recombinant von Willebrand Factor [rVWF] with or without recombinant factor VIII [rFVIII]) are described. Only laboratory parameters (hematology and clinical chemistry) and vital signs (physical examination, ECG) with clinically significant findings that are recorded as AEs are included.
Categories presented as Severity-System Organ Class-Preferred Term
Seriousness: serious adverse event (SAE); non serious adverse event (nsAE)
System Organ Class: Cardiac disorders (CARD); General disorders and administration site conditions (GEN); Investigations (INV); Nervous system disorders (NERV); Skin and subcutaneous tissue disorders (SKN); Vascular disorders (VAS)
Category title includes number of AEs [N] for the category.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
for 12 months after first infusion of rVWF:rFVIII or rVWF
|
||||||||||||||||||||||
Notes [14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Number of subjects with adverse events related to study product including clinically significant changes in laboratory parameters and vital signs [15] | ||||||||||||||||||||||
End point description |
Number of subjects with Adverse Events (AEs) related to study product (recombinant von Willebrand Factor [rVWF] with or without recombinant factor VIII [rFVIII]) are described. Only laboratory parameters (hematology and clinical chemistry) and vital signs (physical examination, ECG) with clinically significant findings that are recorded as AEs are included.
Categories presented as Severity-System Organ Class-Preferred Term
Seriousness: serious adverse event (SAE); non serious adverse event (nsAE)
System Organ Class: Cardiac disorders (CARD); General disorders and administration site conditions (GEN); Investigations (INV); Nervous system disorders (NERV); Skin and subcutaneous tissue disorders (SKN); Vascular disorders (VAS)
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
for 12 months after first infusion of rVWF:rFVIII or rVWF
|
||||||||||||||||||||||
Notes [15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Number of adverse events by infusion related to study product including clinically significant changes in laboratory parameters and vital signs [16] | ||||||||||||||||||||||
End point description |
Adverse Events (AEs) by infusion related to study product (recombinant von Willebrand Factor [rVWF] with or without recombinant factor VIII [rFVIII]) are described. Only laboratory parameters (hematology and clinical chemistry) and vital signs (physical examination, ECG) with clinically significant findings that are recorded as AEs are included.
Categories presented as Severity-System Organ Class-Preferred Term
Seriousness: serious adverse event (SAE); non serious adverse event (nsAE)
System Organ Class: Cardiac disorders (CARD); General disorders and administration site conditions (GEN); Investigations (INV); Nervous system disorders (NERV); Skin and subcutaneous tissue disorders (SKN); Vascular disorders (VAS).
A total of 318 infusions were given.
Category title includes number of AEs by infusion [N] for the category.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
for 12 months after first infusion of rVWF:rFVIII or rVWF
|
||||||||||||||||||||||
Notes [16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Area under the plasma concentration/time curve from time 0 to infinity (AUC0-∞/Dose) of VWF:RCo [17] | ||||||||||||
End point description |
Area under the plasma concentration curve (AUC) from time 0 to infinity of von Willebrand Factor Ristocetin cofactor (VWF:RCo) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Area under the plasma concentration/time curve from time 0 to 96 hours (AUC0-96h/Dose) of VWF:RCo [18] | ||||||||||||
End point description |
Area under the plasma concentration curve (AUC) from time 0 to 96 hours of von Willebrand Factor Ristocetin cofactor (VWF:RCo) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout
|
||||||||||||
Notes [18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Mean Residence Time of VWF:RCo [19] | ||||||||||||
End point description |
Mean Residence Time (MRT) of von Willebrand Factor Ristocetin cofactor (VWF:RCo) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Clearance of VWF:RCo [20] | ||||||||||||
End point description |
Clearance (CL) of von Willebrand Factor Ristocetin cofactor (VWF:RCo) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2)
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Incremental Recovery of VWF:RCo [21] | ||||||||||||
End point description |
Incremental Recovery (IR) at the maximum plasma concentration of von Willebrand Factor Ristocetin cofactor (VWF:RCo) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Elimination Phase Half-Life of VWF:Co [22] | ||||||||||||
End point description |
Elimination Phase Half-Life (T1/2) of von Willebrand Factor Ristocetin cofactor (VWF:RCo) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant FVIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2)..
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Volume of Distribution at Steady State of VWF:RCo [23] | ||||||||||||
End point description |
Volume of Distribution at Steady State (Vss) of von Willebrand Factor Ristocetin cofactor (VWF:RCo) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Area under the plasma concentration/time curve from time 0 to infinity (AUC0-∞/Dose) of VWF:Ag [24] | ||||||||||||
End point description |
Area under the plasma concentration curve (AUC) from time 0 to infinity of von Willebrand Factor Antigen (VWF:Ag) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Area under the plasma concentration/time curve from time 0 to 96 hours (AUC0-96h/Dose) of VWF:Ag [25] | ||||||||||||
End point description |
Area under the plasma concentration curve (AUC) from time 0 to 96 hours of von Willebrand Factor Antigen (VWF:Ag) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Mean Residence Time of VWF:Ag [26] | ||||||||||||
End point description |
Mean Residence Time (MRT) of von Willebrand Factor Antigen (VWF:Ag) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Clearance of VWF:Ag [27] | ||||||||||||
End point description |
Clearance (CL) of von Willebrand Factor Antigen (VWF:Ag) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Incremental Recovery of VWF:Ag [28] | ||||||||||||
End point description |
Incremental Recovery (IR) at the maximum plasma concentration of von Willebrand Factor Antigen (VWF:Ag) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Elimination Phase Half-Life of VWF:Ag [29] | ||||||||||||
End point description |
Elimination Phase Half-Life (T1/2) of von Willebrand Factor Antigen (VWF:Ag) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant FVIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Volume of Distribution at Steady State of VWF:Ag [30] | ||||||||||||
End point description |
Volume of Distribution at Steady State (Vss) of von Willebrand Factor Antigen (VWF:Ag) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Area under the plasma concentration/time curve from time 0 to infinity (AUC0-∞/Dose) of VWF:CB [31] | ||||||||||||
End point description |
Area under the plasma concentration curve (AUC) from time 0 to infinity of von Willebrand Factor Collagen Binding (VWF:CB) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Area under the plasma concentration/time curve from time 0 to 96 hours (AUC0-96h/Dose) of VWF:CB [32] | ||||||||||||
End point description |
Area under the plasma concentration curve (AUC) from time 0 to 96 hours of von Willebrand Factor Collagen Binding (VWF:CB) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Mean Residence Time of VWF:CB [33] | ||||||||||||
End point description |
Mean Residence Time (MRT) of von Willebrand Factor Collagen Binding (VWF:CB) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Clearance of VWF:CB [34] | ||||||||||||
End point description |
Clearance (CL) of von Willebrand Factor Collagen Binding (VWF:CB) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Incremental Recovery of VWF:CB [35] | ||||||||||||
End point description |
Incremental Recovery (IR) at the maximum plasma concentration of von Willebrand Factor Collagen Binding (VWF:CB) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Elimination Phase Half-Life of VWF:CB [36] | ||||||||||||
End point description |
Elimination Phase Half-Life (T1/2) of von Willebrand Factor Collagen Binding (VWF:CB) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant FVIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Volume of Distribution at Steady State of VWF:CB [37] | ||||||||||||
End point description |
Volume of Distribution at Steady State (Vss) of von Willebrand Factor Collagen Binding (VWF:CB) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Area under the plasma concentration/time curve from time 0 to infinity (AUC0-∞/Dose) of FVIII:C [38] | ||||||||||||
End point description |
Area under the plasma concentration curve (AUC) from time 0 to infinity of Factor VIII activity (FVIII:C) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Area under the plasma concentration/time curve from time 0 to 96 hours (AUC0-96h/Dose) of FVIII:C [39] | ||||||||||||
End point description |
Area under the plasma concentration curve (AUC) from time 0 to 96 hours of Factor VIII activity (FVIII:C) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Mean Residence Time of FVIII:C [40] | ||||||||||||
End point description |
Mean Residence Time (MRT) of Factor VIII activity (FVIII:C) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Clearance of FVIII:C [41] | ||||||||||||
End point description |
Clearance (CL) of Factor VIII activity (FVIII:C) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [41] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Incremental Recovery of FVIII:C [42] | ||||||||||||
End point description |
Incremental Recovery (IR) at the maximum plasma concentration of Factor VIII activity (FVIII:C) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Elimination Phase Half-Life of FVIII:C [43] | ||||||||||||
End point description |
Elimination Phase Half-Life (T1/2) of Factor VIII activity (FVIII:C) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant FVIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK50 - Volume of Distribution at Steady State of FVIII:C [44] | ||||||||||||
End point description |
Volume of Distribution at Steady State (Vss) of Factor VIII activity (FVIII:C) after infusion of 50 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) administered together with 38.5 IU/kg recombinant Factor VIII (rFVIII) (ratio of 1.3:1±0.2) [rVWF:rFVIII], or 50 IU/kg VWF:RCo rVWF administered together with saline (placebo) [rVWF] for subjects in the PK50 arms (Arm 1 and Arm 2).
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Area under the plasma concentration/time curve from time 0 to infinity (AUC0-∞/Dose) of VWF:RCo [45] | ||||||||||||
End point description |
Area under the plasma concentration curve (AUC) from time 0 to infinity of von Willebrand Factor Ristocetin cofactor (VWF:RCo) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Area under the plasma concentration/time curve from time 0 to 96 hours (AUC0-96h/Dose) of VWF:RCo [46] | ||||||||||||
End point description |
Area under the plasma concentration curve (AUC) from time 0 to 96 hours of von Willebrand Factor Ristocetin cofactor (VWF:RCo) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Mean Residence Time of VWF:RCo [47] | ||||||||||||
End point description |
Mean Residence Time (MRT) of von Willebrand Factor Ristocetin cofactor (VWF:RCo) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Clearance of VWF:RCo [48] | ||||||||||||
End point description |
Clearance (CL) of von Willebrand Factor Ristocetin cofactor (VWF:RCo) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Incremental Recovery of VWF:RCo [49] | ||||||||||||
End point description |
Incremental Recovery (IR) at the maximum plasma concentration Area under the plasma concentration curve (AUC) from time 0 to infinity of von Willebrand Factor Ristocetin cofactor (VWF:RCo) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Elimination Phase Half-Life of VWF:Co [50] | ||||||||||||
End point description |
Elimination Phase Half-Life (T1/2) of von Willebrand Factor Ristocetin cofactor (VWF:RCo) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Volume of Distribution at Steady State of VWF:RCo [51] | ||||||||||||
End point description |
Volume of Distribution at Steady State (Vss) of von Willebrand Factor Ristocetin cofactor (VWF:RCo) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study PK evaluations at pre-infusion, then at 15, 30 and 60 minutes, and 3, 6, 12, 24, 48, 72 and 96 hours post-infusion.
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Area under the plasma concentration/time curve from time 0 to infinity (AUC0-∞/Dose) of VWF:Ag [52] | ||||||||||||
End point description |
Area under the plasma concentration curve (AUC) from time 0 to infinity of von Willebrand Factor Antigen (VWF:Ag) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Area under the plasma concentration/time curve from time 0 to 96 hours (AUC0-96h/Dose) of VWF:Ag [53] | ||||||||||||
End point description |
Area under the plasma concentration curve (AUC) from time 0 to 96 hours of von Willebrand Factor Antigen (VWF:Ag) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [53] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Mean Residence Time of VWF:Ag [54] | ||||||||||||
End point description |
Mean Residence Time (MRT) of von Willebrand Factor Antigen (VWF:Ag) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Clearance of VWF:Ag [55] | ||||||||||||
End point description |
Clearance (CL) of von Willebrand Factor Antigen (VWF:Ag) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [55] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Incremental Recovery of VWF:Ag [56] | ||||||||||||
End point description |
Incremental Recovery (IR) at the maximum plasma concentration Area under the plasma concentration curve (AUC) from time 0 to infinity of von Willebrand Factor Antigen (VWF:Ag) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [56] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Elimination Phase Half-Life of VWF:Ag [57] | ||||||||||||
End point description |
Elimination Phase Half-Life (T1/2) of von Willebrand Factor Antigen (VWF:Ag) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [57] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Volume of Distribution at Steady State of VWF:Ag [58] | ||||||||||||
End point description |
Volume of Distribution at Steady State (Vss) of von Willebrand Factor Antigen (VWF:Ag) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [58] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Area under the plasma concentration/time curve from time 0 to infinity (AUC0-∞/Dose) of VWF:CB [59] | ||||||||||||
End point description |
Area under the plasma concentration curve (AUC) from time 0 to infinity of von Willebrand Factor Collagen Binding (VWF:CB) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [59] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Area under the plasma concentration/time curve from time 0 to 96 hours (AUC0-96h/Dose) of VWF:CB [60] | ||||||||||||
End point description |
Area under the plasma concentration curve (AUC) from time 0 to 96 hours of von Willebrand Factor Collagen Binding (VWF:CB) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [60] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Mean Residence Time of VWF:CB [61] | ||||||||||||
End point description |
Mean Residence Time (MRT) of von Willebrand Factor Collagen Binding (VWF:CB) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [61] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Clearance of VWF:CB [62] | ||||||||||||
End point description |
Clearance (CL) of von Willebrand Factor Collagen Binding (VWF:CB) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [62] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Incremental Recovery of VWF:CB [63] | ||||||||||||
End point description |
Incremental Recovery (IR) at the maximum plasma concentration Area under the plasma concentration curve (AUC) from time 0 to infinity of von Willebrand Factor Collagen Binding (VWF:CB) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [63] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Elimination Phase Half-Life of VWF:CB [64] | ||||||||||||
End point description |
Elimination Phase Half-Life (T1/2) of von Willebrand Factor Collagen Binding (VWF:CB) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [64] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Volume of Distribution at Steady State of VWF:CB [65] | ||||||||||||
End point description |
Volume of Distribution at Steady State (Vss) of von Willebrand Factor Collagen Binding (VWF:CB) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [65] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Area under the plasma concentration/time curve from time 0 to infinity (AUC0-∞/Dose) of FVIII:C [66] | ||||||||||||
End point description |
Area under the plasma concentration curve (AUC) from time 0 to infinity of Factor VIII activity (FVIII:C) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [66] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK80 - Area under the plasma concentration/time curve from time 0 to 96 hours (AUC0-96h/Dose) of FVIII:C [67] | ||||||||||||
End point description |
Area under the plasma concentration curve (AUC) from time 0 to 96 hours of Factor VIII activity (FVIII:C) after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
Category title includes number of subjects [N] who provided data for the category.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||
Notes [67] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
PK80- Ratio of intra-subject PK of VWF:RCo, VWF:Ag and VWF:CB at baseline and after 6 months [68] | ||||||||||||||
End point description |
Area under the plasma concentration curve (AUC) from time 0 to infinity per dose (AUC0-∞/dose) for von Willebrand Factor Ristocetin cofactor (VWF:RCo), von Willebrand Factor Antigen (VWF:Ag) and von Willebrand Factor Collagen Binding (VWF:CB). Each parameter was compared between the two PK assessments after infusion of 80 IU/kg recombinant von Willebrand Factor:von Willebrand Factor Ristocetin cofactor (VWF:RCo rVWF) [rVWF] for subjects in the PK80 arm (subjects from Arm 3 with PK80 data only).
PK assessment conducted at first infusion of 80 IU/kg rWVF [PK1] and the second infusion of 80 IU/kg rVWF after subjects were treated on demand for bleeding episodes for at least 6 months since their first infusion of study product [PK2].
13 subjects had data available for this endpoint i.e. data for PK1 and PK2.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
PK evaluations at pre-infusion, then at 15, 30 and 60 mins, and 3, 6, 12, 24, 30, 48, 72 and 96 hrs post-infusion.
PK evaluation timeframe for 28 ± 3 days after first infusion of study product which includes PK evaluation for both infusions and washout.
|
||||||||||||||
Notes [68] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, only descriptive statistics were collected for this endpoint. |
|||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
for 12 months after first infusion of recombinant von Willebrand Factor (rVWF) with or without recombinant Factor VIII (rVWF:rFVIII)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
17.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Safety Analysis Set
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
The Safety Analysis Set comprises of subjects who were treated with study product at least once during the study. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
15 Nov 2011 |
Exclusion criteria updated to ensure specific cohort of patients plus hypersensitivity of study product components.
New study arm added (PK80 analysis).
Update for safety stopping rules. |
||
10 Aug 2012 |
Clarification on procedure for enabling home treatment of bleeding episodes.
Inclusion criteria updated to better reflect real life clinical practice for this cohort of patients.
Option to use premixed or sequential infusion of study product (when administered together with recombinant Factor VIII). |
||
26 Jul 2013 |
Final report to be done after completion of study Parts A and B. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |